412
Views
42
CrossRef citations to date
0
Altmetric
Review

Systematic review of trials of the effect of continued use of oral non-selective NSAIDs on blood pressure and hypertension

, , &
Pages 2395-2404 | Accepted 28 Jun 2007, Published online: 21 Aug 2007
 

ABSTRACT

Objective: To investigate the effects of continued use of non-selective NSAIDs (nsNSAIDs) on blood pressure and hypertension.

Research design and methods: This was a systematic review of randomized clinical trials of oral nsNSAIDs used for at least a 4-week duration. Searches were conducted of PubMed and the Cochrane Database of Systematic Reviews, using key terms for nsNSAIDs and blood pressure or hypertension, to identify articles published in the English language peer-reviewed literature through March 2007.

Main outcome measures: Change from baseline to end of study in systolic blood pressure (SBP) and diastolic blood pressure (DBP), and the incidence of hypertension. Pooled statistics were computed using fixed and random-effects analyses.

Results: Thirty-two articles were included. The mean change (95% confidence interval [CI]) in blood pressure (in mmHg) from baseline to end of study for five trials of ibuprofen was 3.54 (2.70, 4.39) for SBP and 1.16 (0.68, 1.64) for DBP ( p < 0.001 for both changes). Results of four trials of indomethacin were similar to those for ibuprofen: 2.90 (–0.28, 6.08) for SBP ( p = 0.07) and 1.58 (0.29, 2.87) for DBP ( p = 0.02). Mean changes from baseline for two trials of diclofenac were –0.46 (–1.48, 0.56) for SBP ( p = 0.38) and –0.56 (–1.19, 0.07) for DBP ( p = 0.08) and were similar to those for placebo. Changes from baseline in SBP were positive but not statistically significant for naproxen, sulindac, and nabumetone. Compared with placebo, the risk ratio (95% CI) for hypertension was 2.85 (1.44, 5.65; p = 0.003) in two ibuprofen trials.

Conclusions: Continued use of ibuprofen increases blood pressure and raises the incidence of hypertension. There appears to be heterogeneity in such effects with continued use of other nsNSAIDs but, due to limitations in the data, results for naproxen, sulindac, and nabumetone are inconclusive.

* A preliminary version of this material was presented at the American Heart Association's Scientific Sessions Conference, November 12–15, 2006, Chicago, IL, USA

* A preliminary version of this material was presented at the American Heart Association's Scientific Sessions Conference, November 12–15, 2006, Chicago, IL, USA

Notes

* A preliminary version of this material was presented at the American Heart Association's Scientific Sessions Conference, November 12–15, 2006, Chicago, IL, USA

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.